A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin

BACKGROUND: The majority of advanced biliary tract cancer (ABTC) patients will progress after gemcitabine and cisplatin (GP) doublet therapy, while the standard second-line regimen has not been established. We conducted this study to assess the efficacy and safety of second-line irinotecan and capec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yi, Tu, Xiaoxuan, Zhao, Peng, Jiang, Weiqin, Liu, Lulu, Tong, Zhou, Zhang, Hangyu, Yan, Cong, Fang, Weijia, Wang, Weilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068158/
https://www.ncbi.nlm.nih.gov/pubmed/29955136
http://dx.doi.org/10.1038/s41416-018-0138-2

Ejemplares similares

Ejemplares similares